TrialIntegrative cancer therapies

A Randomized, Multi-Center, Open Label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy with HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients with EGFR Mutations.

Eunbin Kwag et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.